Determining the effect of glutaredoxin-1 overexpression on the growth of B16F0 tumors in mus musculus by Johnson, Ryan David Patrick
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2017
Determining the effect of
glutaredoxin-1 overexpression on
the growth of B16F0 tumors in mus
musculus
https://hdl.handle.net/2144/23702
Boston University
	 	 	
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
DETERMINING THE EFFECT OF GLUTAREDOXIN-1 OVEREXPRESSION 
 
ON THE GROWTH OF B16F0 TUMORS IN MUS MUSCULUS 
 
 
 
 
 
by 
 
 
 
 
RYAN DAVID PATRICK JOHNSON 
 
B.S., Florida State University, 2015 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2017  
	 	 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2017 by 
 Ryan David Patrick Johnson 
 All rights reserved  
	 	 	
Approved by 
 
 
 
 
First Reader   
 Reiko Matsui, M.D. 
 Assistant Professor of Medicine 
 
 
Second Reader   
 Lija Swain, M.S., Ph.D. 
 Post-Doctoral Researcher
		 iv 
ACKNOWLEDGMENTS 
I would like to extend my deepest gratitude towards my PI, Dr. Reiko Matsui, 
MD.  Without her guidance, support, and knowledge, none of this would have been 
possible.   
I would also like to mention and thank several other deserving individuals who 
have helped me get to this point.  Dr. Lija Swain, M.S., Ph.D., for her support in the lab 
and help writing my thesis.  Dr. Yuko Tsukahara, Ph.D., and Dr. Beatriz Ferrán Pérez, 
Ph.D., for their support in the lab and help in completing this study.  Dr. Yosuke 
Watanabe, M.D., Ph.D., for collecting the initial data that started this study.  Dr. 
Francesca Seta, Ph.D., Dr. Markus Bachschmid, Ph.D., Dr. Jingyan Han, Ph.D., and Dr. 
Shao Di, Ph.D., for their support in lab.  And fellow MAMS student Pavania 
Elavalakanar, for their support in lab and going through this ordeal with me.  
   
  
 
 
 
 
 
 
  
		 v 
DETERMINING THE EFFECT OF GLUTAREDOXIN-1 OVEREXPRESSION 
 
 ON THE GROWTH OF B16F0 TUMORS IN MUS MUSCULUS 
 
RYAN DAVID PATRICK JOHNSON 
ABSTRACT 
Background:  While advances in medicine have led to increased survival rates, cancer is 
responsible for millions of deaths each year.  Melanoma itself accounts for tens of 
thousands of these deaths, and is capable of progressing rapidly.  If left untreated, patient 
prognosis is bad and survival is unlikely.  With distant metastasis, survival rates past five 
years are under ten percent.  The link between angiogenesis and tumor growth has been 
well established, and therefore anti-angiogenic factors should show a decrease or slowing 
of cancer growth.  Glutaredoxin-1 (Glrx), an enzyme residing in the cytosol, is 
responsible for removing glutathione (GSH) from GSH-protein adducts.  This plays a 
role in reversible cellular signaling.  It has been shown that increased levels of global and 
endothelial cell (EC) specific Glrx leads to decreased levels of revascularization 
following hind limb ischemia in mice.  Few studies however have compared the 
overexpression of Glrx to melanoma tumor growth.     
Objective:  To examine how Glrx overexpression in endothelial cells (EC) influences 
B16F0 murine melanoma cell growth in C57BL6 mice. 
Methods:  Eight Glrx overexpressing double transgenic (DTG) and seventeen control 
mice (Ve-cadherin or WT) between the ages of 3 and 4 months old each received 
subcutaneous injection with B16F0 mouse melanoma cells.  After 2 weeks, the mice were 
euthanized to remove tumors.  Weight and size of tumor were recorded.  Tumor, lung, 
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and tail samples were taken.  Real-time polymerase chain reaction (qPCR) of tumor 
samples were performed.  Genotypes were confirmed via western blot of lung and PCR 
of tail DNA.  Excised tumor tissue was in part fixed to examine for angiogenesis and 
macrophage markers.  VEGF ELISA was performed on tumor samples.  
Immunohistochemistry (IHC) testing for Isolectin B4 and CD68 was performed on frozen 
sections.   
Results:  Slightly higher average tumor weight was found in DTG mice (m=1229.45 mg 
± 202.89 mg, n=8) when compared to the control (m=827.32 mg ±172.62 mg, n=17).  
Lower gene expression of VCAM, VEGFA, IL-6, IL-1B, Kdr, and HIF1a was found in 
the DTG mice when compared to the control.  The expression of CD68 was significantly 
lower (P<0.05).  VEGF ELISA showed higher concentrations of VEGF per total protein 
in the DTG mice versus the control mice.  IHC showed DTG had higher endothelial cell 
signaling by Isolectin B4, and higher macrophage signaling by CD68. 
Conclusions:  The growth of B16F0 murine melanoma is not suppressed by the 
overexpression of Glrx in EC of C57BL6 mice.    
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INTRODUCTION 
Tumor Angiogenesis 
 Angiogenesis is the formation of new vasculature from fully formed blood 
vessels, and is regularly occurring, for example during wound healing.  It is widely 
considered to be a necessary factor for the promotion of tumor growth, as the demand for 
nutrients and oxygen is high among these rapidly dividing cells (Folkman 2006).  It was 
established early that multiple types of tumors operate in a hypoxic microenvironment 
(Thomlinson 1955).  Implanted tumors under long term perfusion in vitro have halted 
growth when they reach a diameter of three to four millimeters due to a lack of available 
vasculature (Folkman 1966).  However, we all know that tumors in vivo can keep 
growing and then possibly metastasize to distant locations.  This is due to the capability 
of many tumors to upregulate angiogenesis (Folkman 1971), along with the 
microenvironment the tumors operate in. 
 
Angiogenic Factors 
 One of best environmental factor for the promotion of angiogenesis is hypoxia.  It 
is responsible for hypoxia-inducible factor 1 alpha (HIF1a), which ultimately induces the 
expression of several angiogenic factors, most importantly Vascular Endothelial Growth 
Factor A (VEGFA) (Schaafhausen 2013), also known originally as vascular permeability 
factor.  While there is a family of vascular endothelial growth factors, also including 
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VEGFB, -C, -D, and placental growth factor (Olsson 2006), when the term VEGF is used 
it is often referring specifically to VEGFA.  VEGF is produced by a majority of cells in 
the body but is present in higher levels in hypoxic conditions (Ferrara 2004).  It has been 
one of the most studied factors of tumor angiogenesis.  It has several receptors; VEGFR1, 
known as Flt-1, and VEGFR2, known as Kdr or Flk1.  Upon dimerization by VEGFA, 
Kdr is responsible for the majority of VEGF associated EC migration, proliferation, and 
networking (Murdoch 2014).  But incidentally, VEGF has a higher affinity for Flt-1 than 
its counterpart.  The membrane bound version (mFlt), in response to the ligand VEGF, 
leads to a signal that functions in the same way as Kdr, but with a much-lowered 
response.  Whereas a splice variant soluble version of Flt-1 (sFlt) binds and captures 
VEGF before it can bind to Kdr (Koch 2012, Kendall 1993).  In this way, Flt-1 acts to 
counter the effects of Kdr activation.         
   
S-glutathionylation 
 Reactive oxygen species (ROS) are reactive chemical species which contain 
oxygen.  They are created as a byproduct of metabolism and play important roles in the 
processes of homeostasis and cell signaling (Devasagayam 2004).  It has been noted that 
ROS alter protein function by posttranslational modifications of cysteine thiols (-SH) 
(Burgoyne 2013).  These thiols are able to be oxidized, giving rise to reversible oxidative 
modifications.  These include S-nitrosylation (-SNO) and S-sulfenylation (-SOH) (Wang 
2011).  Both S-sulfenylation and S-nitrosylation are unstable and go on to react with 
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glutathione (GSH), which is the most numerous small intracellular thiol, forming GSH-
protein adducts (Klatt 2000, Wang 2014).  This is called S-glutathionylation (-SSG) 
(Wang 2011).  This protein thiol modification is relatively stable and reversible, and are 
crucial for the regulation of transcription factors and signaling molecules (Figure 1).  
Interestingly enough, S-nitrosylation has been shown to stabilize HIF1a (Li 2007).  
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Glutaredoxin 
 Glutaredoxins (~12kd) are enzymes which belong to the thioredoxin superfamily 
of oxidoreductases.  These are also known as thioltransferases (Mieyal 2008).  Two types 
of glutaredoxin exist in mammalian cells, glutaredoxin-1 (Glrx) and glutaredoxin-2.  Glrx 
is mostly found in the cytosol (Fernandes 2004), and is an efficient catalyst for the 
reduction of GSH-protein adducts (Chrestensen 2000).  This allows it to reverse the 
effects of S-glutathionylation, meaning it can alter cellular processes such as gene 
transcription, cellular signaling, and cytoskeleton dynamics (Shelton 2008, Bachschmid 
2010).  On the contrary, glutaredoxin-2 is found in the nucleus and the mitochondria, and 
in humans is responsible for less than 10% of the activity of Glrx (Lundberg 2001).  
 
NF-kB 
 Nuclear Factor Kappa-light-chain-enhancer of activated B cells, also known as 
NF-kB, is a group of transcription factors in eukaryotes residing in the cytoplasm that 
translocates to the nucleus upon activation.  It is responsible for controlling several 
biological processes, including regulation of the cell cycle, development, apoptosis, and 
inflammation (Hayden 2008, Vallabhapurapu 2009).  The NF-kB complex is made up of 
five factors: RelA (p65), RelB, c-Rel, p50, and p52, along with a number of regulators.  
These NF-kB dimers are held in the cytoplasm by inhibitors called inhibitory kappa B 
(IkB).  These inhibitors are targets of the Inhibitor of nuclear factor kappa-B kinase 
(IKK) complex, which are usually made up of catalytic subunits (IKKa and IKKb) and 
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one regulatory subunit (IKKg).  IKKa and IKKb can then either dimerize with 
themselves or each other, ultimately causing the phosphorylation of the IkBs.  After 
phosphorylation of IkB, the NF-kB dimers become free, move to the nucleus to bind 
DNA, and stimulate gene transcription.  This is called the classical NF-kB pathway 
(Bonizzi 2004).  It is predominantly dependent on IKKb, which phosphorylates the IkBa 
(Ghosh 2002). 
 
Tumor Associated Macrophage 
 When a tumor becomes vascularized, it is inundated with leukocytes.  Tumor 
associated macrophages (TAM), are a class of leukocytes that are often found within or 
in close proximity of tumor tissue.  Originally their presence was though to be due to pre-
existent chronic inflammation.  It is now known that this influx of leukocytes is due to 
the innate and specific immune reaction to tumor cells, and the immune system’s ability 
to see the tumor-associated antigens (Brigati 2002).  In recent years, the notion that better 
prognosis is associated with substancial tumor macrophage infiltration has changed.  In 
addition to tumor cells, TAMs are know to induce the migration of endothelial cells, and 
to also cause their proliferation through the release of proangogenic factors (Dirkx 2006).  
Furthermore, the number of CD68-positive TAMs have been shown to directly correlate 
to the prognosis of malingnant uveal melanoma, via association with higher 
microvascular density (Mäkitie 2001).  And just like VEGF, TAMs often accumulate in 
areas of poor vascularization and hypoxia (Chen 2013). 
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Glutaredoxin Expression 
 The levels of GSH-protein adducts are controlled by an increase or decrease in 
function of Glrx (Murdoch 2014).  The levels of these adducts can alter redox signaling, 
and play a role in various disease states and conditions (Mieyal 2008).  Therefore, Glrx 
also plays a role in these states and conditions.  Plasma levels of Glrx are higher in 
patients with type 2 diabetes (Du 2014).  Increased expression of Glrx is also found in 
allergic mouse airways (Reynaert 2007), the retinas of diabetic rats (Shelton), and human 
coronary arteries with atherosclerosis (Okuda 2001). 
But how does the expression of Glrx affect formation of new blood vessels?  It 
has been shown that its overexpression in vitro inhibits the angiogenic properties of EC 
and VEGF-induced migration of EC (Evangelista 2012).  In instances of mouse hind limb 
ischemia, altering levels of Glrx show very different outcomes.  Overexpression in global 
Glrx transgenic mice experienced hindered blood flow recovery compared to the control 
(Murdoch 2014) (Fig. 2A), while global Glrx knock out mice showed improved 
revascularization (Watanabe 2016) (Fig. 2B).  EC which overexpress Glrx have been 
shown to produce higher levels of sFlt, countering the angiogenic effects of VEGF 
(Murdoch 2014). 
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 Glrx is also able to affect the activity of NF-kB.  GSH addcuts to the cysteines of 
IKKb and NF-kB subunits, preventing the p50 and p65 subunits from binding to DNA, 
inhibiting transcription (Pineda-Molina 2001, Qanungo 2007).  By removing the GSH, 
Glrx increases NF-kB activation (Mieyal 2008, Shelton 2007, Shelton 2009, Murdoch 
2014).  The move of NF-kB dimers to the nucleus has been correlated to increased 
transcription of genes responsible for cytokines, chemokines, adhesion molecules such as 
vascular cell adhesion molecule-1 (VCAM-1), apoptosis inhibitors, and enzymes that 
create secondary inflammatory compunds (Ghosh 1998).  It has been found that 
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chemicals which prevent cancer can disrupt NF-kB activation, while carcinogens and 
oncogenes activate this pathway (Bharti 2002).  The classical NF-kB activation pathway 
encodes several pro-inflammatory chemokines and cytokines.  These factors, such as 
Tumor necrosis factor (TNF), Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 
(IL-8), have been linked to tumor progression in both mice and humans (Balkwill 2001).  
It has also been hypothesized that this pathway could be a link between inflammation and 
tumor promotion (Karin 2002).  
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Preliminary Data 
 
Initial data collected by Yosuke Watanabe, MD, Ph.D. at Boston University 
School of Medicine, showed EC specific transgenic mice exhibit impaired limb 
vascularization after receiving hind limb ischemia surgery (Figure 3).  Also as part of 
this initial data, Matrigel containing VEGF implanted subcutaneously in EC-Glrx DTG 
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mice showed a significantly lower amount of hemoglobin when compared to the control, 
implying decreased amounts of blood flow and vascularization (Figure 4).  Matrigel 
containing no factors (Vehicle) showed no discernable blood flow across both groups. 
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OBJECTIVES 
The increased expression of global and endothelial specific glutaredoxin-1 has 
been found to inhibit the recovery from hind limb ischemia surgery in laboratory mice 
when the femoral artery is ligated.  This is due to an increased expression of anti-
angiogenic factors. It has been shown that cancer growth is dependent on available blood 
supply and constant neovascularization.  Therefore, it is reasonable to hypothesize that 
increased expression of Glrx in EC may inhibit tumor angiogenesis and growth.  
However, initial preliminary data shows EC-Glrx mice having a higher average tumor 
weight when compared to the control (Figure 5).  This paper seeks to further examine 
how increased Glrx expression in EC influences B16F0 murine melanoma cell growth in 
C57BL6 mice. 
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METHODS 
Animal Model 
 All animals were treated in a manner approved by the Laboratory Animal Science 
Center (LASC) on the Medical Campus at Boston University and consistent with the 
guidelines laid out by the ‘Guide for the Care and Use of Laboratory Animals: Eight 
Edition’ (National Research Council. 2011).  
 
 C57BL/6 VEcad-tTA (Jackson Laboratory) and C57BL/6 tetO-Glrx (Yvonne 
Janssen-Heininger, Ph.D., University of Vermont) laboratory mice were bred to create 
EC-specific Glrx DTG mice (Figure 6).  The DTG mice express Tetracycline 
transactivator (tTa), which binds to the Tetracycline operating element (tet-O).  This 
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causes the induction of the Flag-Glrx transgene.  This is a system that only functions 
when there is no doxycycline present, known as DOX-off system.  Four supplemental 
WT control mice (ID – 228533 NN, 228533 RN, 228533 LN, 228533 BN) were 
purchased from The Jackson Laboratory.  All mice were kept under normal housing and 
diet conditions until injections occurred between three and five months of age.  WT and 
VE-cadherin were used as the control.  All mice used in the study are listed in the table 
Tumor Implants. 
B16F0 murine melanoma was acquired from Nader Rahimi, Ph.D. (Boston 
University School of Medicine), and was cultured in ThermoFisher Scientific high 
glucose Dulbecco’s Modified Eagle Medium (11965-092) with a concentration of ten 
percent fetal bovine serum.  After the cells were trypsinized and cell numbers were 
estimated using a hemocytometer, they were suspended in Corning Matrigel Growth 
Factor Reduced Basement Membrane Matrix (356231).  DTG mice (n=8), along with 
control mice (VE-cadherin or WT, n=17) between three to five months of age were 
injected with 4x10^5 cells of B16F0 mouse melanoma in two hundred µL of Matrigel.   
Mice were anesthetized using an isoflurane vaporizer and nose cone, and injections were 
administered in subcutaneous space at the right backside of the animal.  All injections 
occurred in the dedicated animal surgery room of the laboratory.  Mice were monitored 
until they regained consciousness, and then taken back to the animal facility for the 
remainder of the experiment.  Prior to injection and two weeks after injection, mouse 
weight was recorded.  Two weeks after injections, mice were euthanized and samples 
were collected.  Tails were collected for genotyping, lungs for confirmation of FLAG via 
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western blot, and tumors for real-time polymerase chain reaction (qPCR), VEGF 
enzyme-linked immunosorbent assay (ELISA), and IHC (Figure 7).  Weight and 
dimensions of excised tumors were recorded in the Tumor Data table. 
 
 
Genotyping 
Tails were cut into small pieces for genotyping.  They were then put into an alkaline tail 
lysis buffer (NaOH 25 nM, EDTA 0.2 mM) at ninety-five degrees Celsius for an hour, 
cooled, and subsequently quenched with 40 mM pH 5Tris/HCl buffer to isolate the DNA.  
PCR was performed using the following Invitrogen primers; IMR8746 
(CGCTGTGGGGCATTTTACTTTAG), IMR8747 (CATGTCCAGATCGAAATCGTC), 
IMR9020 (AAGGGAGCTGCAGTGGAGTA), IMR9021 
(CCGAAAATCTGTGGGAAGTC), flag Glrx 1 F (ATGGACTACAAGGACGACGA), 
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flag Glrx 4 R (ATCTGCTTCAGCCGAGTCAT), flag Glrx 2 R 
(GGGCTTAGATGGCGATACTC), flag Glrx 3 F (AACAACACCAGTGCGATTCA).  
The amplified DNA was then run on 1.2% agarose gels before being viewed under 
ultraviolet light to confirm genotype (Figure 8).  On the far left is the ladder (NEB – 
N0467S), followed by two WT mice, three Tet mice (not used for the purposes of this 
study), and finally two DTG mice. 
 
 
Tumor Implants 
Mouse ID Gender Genotype Age 
453501 RN F DTG 3 months, 22 days 
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453501 BN F DTG 3 months, 22 days 
451374 LN M DTG 3 months, 15 days 
452454 RN M DTG 3 months, 14 days 
452454 LN M DTG 3 months, 14 days 
456891 RN F DTG 4 months, 6 days 
456892 NN M DTG 4 months, 6 days 
457340 LN M DTG 4 months, 3 days 
448729 NN F VE-cadherin 5 months, 5 days 
453501 NN F VE-cadherin 3 months, 22 days 
451374 RN M VE-cadherin 3 months, 15 days 
451374 NN M VE-cadherin 3 months, 15 days 
456891 NN F VE-cadherin 4 months, 6 days 
458668 RN M VE-cadherin 3 months, 22 days 
453501 LN F WT 3 months, 22 days 
451374 BN M WT 3 months, 15 days 
451373 NN F WT 3 months, 15 days 
452453 NN F WT 3 months, 14 days 
456891 LN F WT 4 months, 6 days 
228533 NN F WT 3 months, 29 days 
228533 LN F WT 3 months, 29 days 
228533 RN F WT 3 months, 29 days 
228533 BN F WT 3 months, 29 days 
457340 RN M WT 4 months, 3 days 
457340 NN M WT 4 months, 3 days 
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Confirmation of FLAG 
Lungs from euthanized mice were frozen in liquid nitrogen for preservation, and 
then thawed when needed.  Lung protein was extracted.  This was done by filling two mL 
screw top tubes with zirconium beads.  Two-hundred µL of lysis buffer (1M Tris-HCl 
[pH 7.4], 5M NaCl, 500 mM EDTA, 10% Triton X-100, H2O) and two µL of protease 
phosphatase inhibitor was added to each tube.  A small piece of lung tissue was then 
added to each tube.  The samples were homogenized using a Roche MagNA lyser, and 
lysed for ten seconds at six-thousand rpm, for four times total, sitting on ice for five 
minutes between each cycle.  The lysis buffer along with the homogenized tissue was 
transferred into fresh Eppendorf tubes, which were centrifuged at thirteen-thousand RPM 
for thirty minutes.  The supernatant of these tubes was transferred to another set of 
Eppendorf tubes.   
The concentration of the extracted protein was then confirmed by protein assay.  
A standard was prepared using bovine serum albumin (BSA) and distilled water.  The 
concentrations consist of 2, 1, 0.5, 0.25, and 0.125 mg/mL.  Five µL of each standard and 
sample were placed in separate wells of a ninety-six well plate.  Twenty-five µL of 
Reagent A from a Bio-Rad Laboratories DC™ Protein Assay kit (5000112) was added to 
each well.  Then Two-hundred µL of Reagent B from the same kit was added to each 
well.  The plate was allowed to wait at room temperature for fifteen minutes.  It was then 
read immediately at 750 nm.   
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Western blotting was then performed, which confirmed the presence of FLAG 
(Figure 9).  This in addition to genotyping, confirmed if a mouse was DTG.  All mice 
that were genotyped as being DTG were confirmed as being DTG via western blotting. 
 
  
Real-Time Polymerase Chain Reaction 
 Part of six DTG and six control frozen tumor samples were thawed, and using a 
Zymo Research Quick-RNAä MiniPrep Plus kit, RNA was extracted.  These samples 
were chosen at random from both genders of each respective group.  The ID’s of these 
mice are in the Genotype of qPCR Mice table. 
 
Genotype of qPCR Mice 
ID Gender Genotype 
453501 RN F DTG 
	19 
453501 BN F DTG 
451374 LN M DTG 
452454 RN M DTG 
456891 RN F DTG 
456892 NN M DTG 
448729 NN F VE-cadherin 
451374 NN M VE-cadherin 
456891 NN F VE-cadherin 
453501 NN F WT 
453501 LN F WT 
228533 RN F WT 
 
One µg of the isolated RNA was then used to perform reverse transcription 
polymerase chain reaction (RT-PCR) using Applied Biosystemsä High Capacity RNA-
to-cDNA Kitä, creating complementary DNA (cDNA).  The cDNA and Applied 
Biosystemsä TaqManâ Gene Expression Master Mix was then used to perform qPCR in 
a ninety-six well Applied Biosystemsä qPCR plate.  Each well received ten µL of Master 
Mix, eight µL of water, and one µL each of cDNA and relevant gene expression assay.  
Applied Biosystemsä TaqManâ Gene Expression Assays were used to measure the 
expression of seven genes using mouse b-actin (4352933E) as the control.  The genes 
quantified were VCAM (Mm01320970_m1), VEGFA (Mm01281449_m1), IL-6 
(Mm00446190_m1), IL-1B (Mm00434228_m1), CD68 (Mm03047343_m1), Kdr 
(Mm01222421_m1), and HIF1a (Mm00468878_m1).  Comparisons were made and then 
relative expression graphed using GraphPad Prism. 
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VEGF ELISA 
 Part of tumors from eight DTG and seventeen control mice were thawed and 
protein was extracted.  This protein extract was then stored in negative eighty degrees 
Celsius.  It was used to calculate the pg of VEGF present per µg of protein present in the 
sample, using a RayBio Ò Mouse VEGF ELISA Kit (ELM-VEGF-1).  This type of 
ELISA is of the “sandwich” type.    
 All reagents and samples were brought to room temperature before use, and all 
standards and samples were run in duplicate.  One hundred µl of standards and samples 
were put into appropriate wells of the ninety-six well ELISA plate, which was then 
allowed to incubate overnight at four degrees Celsius.  Wells were washed with the 
provided wash solution, then filled with one hundred µl of provided biotinylated antibody 
and allowed to incubate at room temperature for one hour.  The washing step was 
performed again, followed by the addition of one hundred of provided Streptavidin 
solution to each well.  It was allowed to incubate for forty-five minutes at room 
temperature.  Washing was performed again.  One hundred µl of TMB One-Step 
Substrate Reagent was added to each well and incubated at room temperature in the dark 
for half an hour.  Fifty µl of Stop Solution was added to each, and the entire plate was 
immediately read at four hundred and fifty nm.  A protein assay of the samples was 
performed after this, and the concentration data was used to normalize the ELISA.  
Results were graphed using Graphpad Prism.     
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Immunohistochemistry  
Excised tumors were fixed using first a ten percent formalin solution or a four 
percent paraformaldehyde (PFA) solution overnight.  After twenty-four hours, this was 
replaced with phosphate buffered saline (PBS).  The tumors were transferred to a ten 
percent sucrose solution and then a twenty percent sucrose solution over the next two 
days.  The tumors were frozen in Fisher Healthcare™ Tissue-Plus™ optimal cutting 
temperature (OCT) compound, and then cut on a cryostat to create slides.  These slides 
underwent initial IHC, to detect the effectiveness of the fixation.  It was determined that 
the ten percent formalin solution was not ideal, and the change of fixation solution was 
made.  Slides from frozen sections belonging to samples that were fixed with four percent 
PFA underwent IHC.  DTG (n=3) and Control (n=9) were stained with primary 
antibodies testing for Isolectin B4 (Vector Laboratories; FL-1201), an endothelial cell 
marker, and CD68 (Bio-Rad Laboratories; MCA1957A488T), a macrophage marker.  
The total number of DTG mice available for IHC was fewer than the total because it was 
discovered that the ten percent formalin fixation was not ideal, and the switch to four 
percent PFA was made for the rest of the study.   
After frozen samples were cut and placed onto Fisherbrand Superfrost Plus 
Microscope Slides, the slides were placed in a negative twenty-degree Celsius freezer for 
storage.  When needed for IHC, their slide box was allowed to warm up to room 
temperature before opening.  The slides were washed in tris-buffered saline (TBS) plus 
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0.025 percent Triton X-100 with gentle agitation twice for five minutes each with gentle 
agitation.  The slides were drained and a Vector Laboratories ImmEdge™ Pen was used 
to mark the boundaries of each tissue sample.  They were then blocked with one percent 
BSA in TBS for one hour at room temperature.  They were drained again and tissue paper 
was used to wipe around each section.  Primary antibodies were diluted in one percent 
BSA in TBS to the required amount set by the manufacturer and then applied to sections. 
The sections were then incubated overnight at four degrees Celsius.  Once again, the 
slides were washed three times with TBS plus 0.025 Triton for five minutes each.  The 
Vector Laboratories Isolectin B4 and Bio-Rad Laboratories CD68 primary antibodies are 
fluorophore-conjugated, so these slides were incubated in one percent BSA in TBS in the 
same conditions as those receiving a secondary antibody.  Slides were rinsed three times 
for five minutes each with TBS.  Glass coverslips were mounted to the slides using 
Calbiochem FluorSave™ Reagent, and the slides were kept in darkness until viewing the 
next day.   
These signals were viewed either under a fluorescein isothiocyanate (FITC) 
setting to view Vector Laboratories Isolectin B4 (x10 magnification) and Bio-Rad 
Laboratories CD68 (x20 magnification), and then viewed under the 4’,6-diamidino-2-
phenylindole (DAPI) setting to view tissue wide endogenous nuclear signaling which was 
used as a control.  This was done on a Nikon deconvolution wide-field Epifluorescence 
microscope, provided by the Boston University Medical Campus Cellular Imaging Core.  
Large field composite images of two by two fields of view were created using the native 
Nikon microscope software, to ensure as much sample as possible was viewable.  Images 
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were then analyzed using the threshold function in ImageJ to determine the extent of 
expression, and graphs of the data were made using Graphpad Prism. 
 
Statistical Analysis 
 All data is shown as mean ± SE with number of samples.  Two-tailed t test 
(heteroscedastic) was used to determine P values using Microsoft Excel software.  A P 
value of less than 0.05 is considered statistically significant. 
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RESULTS 
Tumor 
Analysis of tumor weights showed a trend of increase in the DTG mice 
(m=1229.45 mg ± 202.89 mg, n=8) when compared to the control group (m=827.32 mg 
±172.62 mg, n=17) (P=0.138) (Figure 10).  This was conserved when comparing either 
both genders together or each gender separately.  The male DTG (m=1165.38 mg ± 
303.82 mg, n=5) showed a higher mean over the male control (m=625.28 mg ± 151.11 
mg, n=6) (P=0.163) (Figure 11).  The same was seen in the female DTG (m=1357.43 mg 
± 272.93 mg, n=3) and control (m=937.53 mg ± 253.06 mg, n=11) (P=0.294) (Figure 
12). Interestingly, when comparing both genders, removing the one mouse that was over 
five months old and the purchased Jackson Laboratories Mice, the DTG mice 
(m=1229.45 mg ± 202.89 mg, n=8) were significantly larger (P=0.049) than the control 
mice (n=677.04 mg ± 160.46 mg, n=12).  However, these mice were used for analysis of 
mRNA or IHC.  Therefore, I included all mice to present in the results in this thesis.  If 
the number of samples in the same cohort was increased, it might show significant 
increase in tumor size in DTG mice. 
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Tumor Data 
ID Gender Genotype Age Tumor 
Weight 
(mg) 
Body 
Weight 
(g) 
Length 
(mm) 
Width 
(mm) 
Height 
(mm) 
453501 
RN 
F DTG 3 months, 
22 days 
1532.7 22.3 19.97 14.23 10.57 
453501 
BN 
F DTG 3 months, 
22 days 
 
 
822.1 23.3 16.88 10.85 8.13 
451374 
LN 
M DTG 3 months, 
15 days 
1634.9 27.6 19.77 14.91 9.24 
452454 
RN 
M DTG 3 months, 
14 days 
1559.4 28.7 17.15 13.85 9.19 
452454 
LN 
M DTG 3 months, 
14 days 
171.6 25.7 12.76 9.34 3.17 
456891 
RN 
F DTG 4 months, 
6 days 
1717.5 22.3 21.04 12.57 9.69 
456892 
NN 
M DTG 4 months, 
6 days 
1653.9 32.7 19.48 13.02 10.54 
457340 
LN 
M DTG 4 months, 
3 days 
743.5 27.1 16.90 10.92 7.08 
448729 
NN 
F VE-
cadherin 
5 months, 
5 days 
1174.8 22.5 18.35 11.35 7.01 
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453501 
NN 
F VE-
cadherin 
3 months, 
22 days 
517.6 19.9 13.87 9.54 6.64 
451374 
RN 
M VE-
cadherin 
3 months, 
15 days 
174.5 31.9 17.5 5.92 2.59 
451374 
NN 
M VE-
cadherin 
3 months, 
15 days 
956.2 32.9 18.07 11.98 7.81 
456891 
NN 
F VE-
cadherin 
4 months, 
6 days 
2097.8 22.3 19.21 17.20 10.64 
458668 
RN 
M VE-
cadherin 
3 months, 
22 days 
361.5 22.2 15.60 7.81 3.66 
453501 
LN 
F WT 3 months, 
22 days 
967.8 21.9 24.59 12.5 9.44 
451374 
BN 
M WT 3 months, 
15 days 
904.6 32.1 16.52 10.93 4.95 
451373 
NN 
F WT 3 months, 
15 days 
183.7 22.9 10.58 5.60 2.68 
452453 
NN 
F WT 3 months, 
14 days 
151.4 20.9 10.32 7.21 8.59 
456891 
LN 
F WT 4 months, 
6 days 
454.5 22.9 13.49 9.41 6.67 
228533 
NN 
F WT 3 months, 
29 days 
225.4 20.7 8.51 10.20 5.94 
228533 
LN 
F WT 3 months, 
29 days 
324.9 21.9 11.88 7.84 6.62 
228533 
RN 
F WT 3 months, 
29 days 
1648 21.6 19.25 12.73 10.87 
228533 
BN 
F WT 3 months, 
29 days 
2567 20.3 21.41 13.96 11.41 
457340 
RN 
M WT 4 months, 
3 days 
346.5 29.3 15.44 9.44 5.15 
457340 
NN 
M WT 4 months, 
3 days 
1008.4 28.3 14.28 7.94 11.21 
 
 
qPCR 
The qPCR data showed a trend of lower expression of all tested genes in the DTG 
group when compared to the control group but the difference was not significant (Figure 
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13).  Relative quantity (RQ) was standardized by b-actin.  In particular, the expression of 
CD68 in the DTG (RQ=0.461) was significantly lower than the control (RQ=0.957) 
(P=0.033). 
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qPCR Data 
Gene Average (RQ) S.D. (RQ) S.E. (RQ) 
VCAM (DTG) 0.391 0.255 0.104 
VCAM (Control) 0.671 0.489 0.199 
VEGF (DTG) 0.834 0.277 0.113 
VEGF (Control) 1.102 0.459 0.187 
IL-6 (DTG) 0.685 0.140 0.062 
IL-6 (Control) 1.728 1.315 0.537 
IL-1B (DTG) 1.675 1.412 0.576 
IL-1B (Control) 3.345 3.974 1.622 
CD68 (DTG) 0.461 0.160 0.065 
CD68 (Control 0.957 0.422 0.172 
Kdr (DTG) 0.370 0.191 0.078 
Kdr (Control) 0.608 0.287 0.117 
HIF1a (DTG) 0.506 0.287 0.117 
HIF1a (Control)    0.715 0.249 0.102 
 
ELISA 
The mouse VEGF ELISA kit shows that the DTG mice had increased 
concentration of VEGF per total protein (m=494.45 pg/µg ± 84.82 pg/µg, n=8) when 
compared to the control (m=322.36 pg/µg ± 32.43 pg/µg, n=17) (P=0.090) (Figure 14).  
While not significant, there is an upward trend.  This trend is conserved between genders.  
Male DTG mice (m=503.24 pg/µg ± 103.71 pg/µg, n=5) have an insignificantly higher 
average than the male control (m=288.20 pg/µg ± 27.99 pg/µg, n=6) (P=0.106) (Figure 
15).  The female DTG mice (m=479.81 pg/µg ± 176.40 pg/µg, n=3) also had an 
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insignificantly higher average than the female control (m=340.99 pg/µg ± 49.41 pg/µg, 
n=11) (P=0.517), but the n is small (Figure 16).   
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ELISA Data 
ID Gender Genotype pg VEGF / µg total 
protein 453501 RN F DTG 265.454 
453501 BN F DTG 829.655 
451374 LN M DTG 721.121 
452454 RN M DTG 327.553 
452454 LN M DTG 320.168 
456891 RN F DTG 344.329 
456892 NN M DTG 789.713 
457340 LN M DTG 357.674 
453501 NN F VE-cadherin 570.640 
451374 RN M VE-cadherin 247.155 
451374 NN M VE-cadherin 381.496 
456891 NN F VE-cadherin 264.589 
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458668 RN M VE-cadherin 315.931 
453501 LN F WT 258.117 
451374 BN M WT 339.105 
451373 NN F WT 67.189 
452453 NN F WT 168.898 
456891 LN F WT 534.214 
228533 NN F WT 286.802 
228533 LN F WT 505.354 
228533 RN F WT 502.562 
228533 BN F WT 319.668 
457340 RN M WT 198.306 
457230 NN M WT 247.213 
 
 
Immunohistochemistry 
The DTG mice available for IHC showed a slightly higher level of Isolectin B4 
signal expression (m=0.04579 FITC/DAPI ± 0.01213 FITC/DAPI, n=3) when compared 
to the control group (m=0.04238 FITC/DAPI ± 0.00557 FITC/DAPI, n=9) (Figure 18).  
This was not significant (P=0.815).   
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They also showed insignificantly higher levels of CD68 signaling (m=0.01491 
FITC/DAPI ± 0.00389 FITC/DAPI, n=3) when compared to the control (m=0.01096 
FITC/DAPI ± 0.00216 FITC/DAPI, n=9) (P=0.434) (Figure 20). 
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IHC Data 
ID Genotype FITC/DAPI 
(Isolectin B4) 
FITC/DAPI 
(CD68) 
458668 RN VE-cadherin 0.03766 0.00896 
456891 NN VE-cadherin 0.05749 0.00057 
457340 RN WT 0.05754 0.00931 
457340 NN WT 0.05615 0.01436 
456891 LN WT 0.02962 0.01383 
228533 RN WT 0.03972 0.00815 
228533 NN WT 0.02347 0.01401 
228533 LN WT 0.06254 0.02358 
228533 BN WT 0.01723 0.00585 
457340 LN DTG 0.06150 0.02239 
456892 NN DTG 0.05396 0.00929 
456891 RN DTG 0.02191 0.01305 
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DISCUSSION 
B16F0 Tumors 
The initial pilot data showed that the tumors of the DTG mice were larger on 
average as a trend when compared to their control counterparts.  This was also seen in 
this study.  This finding was surprising but also interesting.  The established phenomenon 
of global Glrx overexpression lowering revascularization from hind limb ischemia 
surgery, and initial data showing that the same impaired vascularization occurs in EC-
specific Glrx overexpressing mice, makes one hypothesize reduced tumor growth in these 
mice.  Tumors are dependent on an adequate supply of blood, and it could be expected 
that hindering the ability of the tumors to form new vasculature would limit their growth.  
Yet, tumor cells by themselves are able to promote their own growth.  Human melanoma 
xenografts in nude mice show that melanoma cells are a source of growth factors, which 
include VEGF (Wanebo 2006).  Ultimately, after performing t-tests upon the control and 
DTG tumor weights, results were not significant (P=0.138).  This was the case comparing 
tumors from only male mice (P=0.163), as well as only female mice (P=0.294).  The 
tumors may not even be completely reliant on EC to supply needed blood flow.  Through 
a mechanism called vasculogenic mimicry, tumor cells engage in new blood 
development.  These cells express genes similar to EC during angiogenesis (van der 
Schaft 2004).  Signaling pathways related to vascularization and hypoxia are upregulated 
during this phenomenon (Kirschmann 2012).  Whatever the case, the conclusion can be 
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reached that EC-Glrx overexpression does not inhibit the growth of B16F0 murine 
melanoma despite the anti-angiogenic effects in ischemic limb revascularization.   
 
VEGFA and Angiogenesis 
The DTG mice showed a trend of higher levels of VEGFA when compared to the 
control from the ELISA results.  This trend was only observed when viewing the 
averages.  There are several instances where a relatively large tumor has the same 
concentration of VEGF of a smaller tumor.  Therefore, a higher VEGF concentration 
does not seem to directly correspond to a larger size tumor in both the DTG and control 
mice.  It is known that VEGFA is induced via HIF1a in hypoxic tissue.  One possibility 
is that the tumors of the DTG mice have higher levels of HIF1a due to the 
overexpression of Glrx in their EC.  This may cause less tumor angiogenesis and 
therefore lead to tissue hypoxia, which stabilizes HIF1a.  However, the qPCR data 
showed that the DTG group did not increase gene expression of VEGFA in tumor tissue 
when compared to the control.  The DTG group also showed lower gene expression of 
Kdr, VEGFA’s most effective receptor.  We need more numbers of DTG mice to 
determine if the VEGF protein level is higher or not in their tumors.  If it is higher, 
possibly lower mRNA expression could be due to a negative feedback loop due in 
response to the higher VEGFA levels.  However, Isolectin B4 data indicates no 
significant difference in EC density between the DTG and control.  Likely, angiogenesis 
in tumor was neither impaired nor increased by Glrx overexpression in EC.     
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Macrophages 
 The IHC staining for Isolectin B4 (EC marker) shows slightly higher amounts of 
endothelial cells on average compared to the control tumors, but not significantly 
different.  Infiltrating leukocytes such as macrophages also produce VEGF or other 
angiogenic factors that play important roles in tumor growth (Coffelt 2010).  In severe 
combined immunodeficiency (SCID) mice with breast tumors, anti-VEGF therapy 
reduced tumor microvasculature density and the infiltration of TAMs (Roland 2009).  
The DTG mice also showed insignificantly higher staining from CD68, a glycoprotein 
which is expressed on macrophages (Taylor 2005).  This could imply a higher number of 
macrophages infiltrating the tumor tissue.  Be that as it may, CD68 expression was 
significantly lower by assessing mRNA in the tumors of DTG mice.  It is one possibility 
that this could be due to a negative feedback loop, as mentioned previously.  An 
increased sample size of tumors for IHC is needed to further elaborate on these 
possibilities. 
 
NF-kB 
 In the introduction, it was stated that Glrx actually increases the activation of NF-
kB (Mieyal 2008, Shelton 2007, Shelton 2009, Murdoch 2014).  This increased activation 
leads to an upregulation of proinflammatory factors such as cytokines and chemokines, 
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including TNF, IL-1, IL-6, and IL-8 (Balkwill 2001).  The increased tumor size in the 
DTG mice could be from the overactivation of the NF-kB pathway in EC.  If EC produce 
cytokines or tumor-growth factor by hyperactivation of NF-kB, it may stimulate tumor 
growth.  We tested the gene expression of two of these factors (IL-1, IL-6), and the DTG 
group showed lower levels when compared to the control.  Just as in the case of Kdr, 
VEGFA, and CD68, this could possibly be due to a negative feedback loop, where levels 
of IL-1 and IL-6 in the tissue are increased.  However this is purely conjecture until more 
data is collected.  It will be a priority to check the concentration and gene expression of 
TNF, as it plays an important role in the regulation of immune cells via apoptosis.  It can 
also lead to the activation of the NF-kB pathway (Wajant 2003).  Depending on the levels 
of TNF, this could help explain the difference in tumor weight and macrophage 
infiltration between the DTG mice and the control.  In order to assess cytokine levels in 
the tumors, performing a multiplex to test multiple analytes of interest in a single assay is 
planned for the future. 
   
Limitations and Future Plans 
The number of cells were counted by hemocytometer, and mixed in Matrigel 
evenly, but there could have been differences in the number of cells injected into each 
mouse due to technical inconsistency between tumor cell preparations or between mice.  
That could cause high standard deviation in tumor weight in the results.  To perform the 
qPCR, six DTG and six control mice were chosen due to the limit of wells available per 
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qPCR plate.  This means that the trends noted in the data might have been different 
depending on which samples were chosen.  Luckily there were few enough DTG in total 
so that there would be significant overlap between DTG mice chosen.  qPCR was run for 
some genes more than twice, and the results were similar.  Therefore, technical errors 
such as potential pipetting errors were unlikely. 
The fixation of tumors bound for IHC with a ten percent formalin solution 
unintentionally led to small pool of DTG to use in the final data.  In the future, all of the 
samples to be used for IHC or staining will be preserved with a four percent PFA solution 
for a shorter time.  Also in the future, it is planned to create paraffin slides of tumors, for 
hematoxylin and eosin staining.  There were several attempts at running a western blot on 
tumor protein to measure the detectable levels of HIF1a, however all attempts failed.  
Moving forward, attempting to gain measurable results of HIF1a expression should be 
accomplished. 
It would be ideal to increase the number of mice for the study.  There were only 
eight DTG mice in total bred in time for this thesis, compared to the seventeen of the 
control group.  Because we bred VE-cadherin +/- and tet-Glrx +/- mice, a quarter of all 
pups produced are DTG.  Therefore, to increase the amount of DTG mice available for 
the study, more breeding needs to occur.  As a larger sample size would increase the 
accuracy of results and reduce the standard error, a study consisting of mice from both 
genders is required.  Interestingly, tumor size tended to be larger in female control mice 
compared to male control mice, and the effect of DTG was blunted in females.  
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Therefore, comparison between genders with an increased number of mice will be 
interesting. 
Letting the tumors grow for a longer time period (three to four weeks) may allow 
for more differences in vasculature to be observed.  Changing the type of melanoma 
injected into the mice would also be new avenue to explore, as B16F0 is non-invasive 
and does not metastasize.  It has been shown that Glrx overexpression protects the barrier 
function and decreases the permeability of EC.  This is due to the removal of harmful 
protein S-glutathionylation brought on by the metabolic stresses of diabetes and 
hyperlipidemia (Han 2016).  This mechanism remains to be elucidated.  Switching to 
B16F10 (metastatic murine melanoma) may show how this reduced vascular permeability 
affects extravasation of the tumor cells and subsequent metastasis.   
Also, using Glrx-KO or global-Glrx TG mice instead of the EC-Glrx mice is 
worth pursuing, after this study is completed.  Would the tumor size be found smaller in 
the KO mice?  How would global Glrx overexpression affect the tumor size and other 
factors? 
In conclusion, EC-Glrx DTG mice do not inhibit the growth of B16F0 melanoma 
in Mus musculus, in contrast to our expectation.  The results of this study do look very 
interesting.  Although the data is not statistically significant yet, DTG mice showed as a 
trend larger tumors, as well as higher levels of VEGF, lower gene expression of CD68, 
and higher tumor infiltration of CD68+ macrophages.  This is a rare example showing 
discrepancy between ischemic limb angiogenesis and tumor growth.  Further studies will 
elucidate the mechanism of tumor angiogenesis and growth.  
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